Oops! This Content is Members Only

Recent Content

• Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma
• Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia
• Shah on the Potential Utility of NK Cells in Multiple Myeloma
• Dr. Popat on Investigational Strategies for Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma
• Monoklonal gammopati av klinisk betydning
• Roadmap to cure multiple myeloma
• Oncopeptides withdraws multiple myeloma therapy from U.S. market
• The Myeloma Nurse Who Climbed a Mountain to Connect With Her Patients
• Oncopeptides Withdraws Melphalan Flufenamide Myeloma Indication in the United States
• Driving Treatment Decisions and Predicting Long-Term Outcomes in Multiple Myeloma